18 assets in Hyperinsulinism

Therapeutic assets addressing Hyperinsulinism, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Metformin Hyperinsulinism	Attikon Hospital	P4	BB (67)
Eudemine Injection Hyperinsulinism	Columbia University	P2	B (61)
Vigabatrin Hyperinsulinism	University of Arizona	P2	CCC (53)
[6,6-2H2] D-glucose Hyperinsulinism	Columbia University	P1	CC (44)
Alpelisib Hyperinsulinism	Columbia University	P1	CC (44)
Deuterated Water Hyperinsulinism	Columbia University	P1	CC (44)
Glucagon Hyperinsulinism	Columbia University	P1	CC (44)
Glucose, Anhydrous Hyperinsulinism	Columbia University	P1	CC (44)
Insulin Human Hyperinsulinism	Columbia University	P1	CC (44)
L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R,R))- Hyperinsulinism	Columbia University	P1	CC (44)
Serostim Hyperinsulinism	Columbia University	P1	CC (44)
Dapagliflozin Hyperinsulinism	Yale University	P1	CC (43)
Dextrose Solution Hyperinsulinism	Columbia University	P1	CC (41)
Pioglitazone Hyperinsulinism	Rambam Health Care Campus	Early P1	C (39)
Dextrose Hyperinsulinism	University of Colorado, Denver	N/A	D (30)
Gnrh Hyperinsulinism	University of Colorado, Denver	N/A	D (30)
Heparin Hyperinsulinism	University of Colorado, Denver	N/A	D (30)
Intralipid Hyperinsulinism	University of Colorado, Denver	N/A	D (30)